In vitro activity of AR-709 against Streptococcus pneumoniae

W T M Jansen; A Verel; J Verhoef; D Milatovic

doi:10.1128/AAC.01332-07

In vitro activity of AR-709 against Streptococcus pneumoniae

Antimicrob Agents Chemother. 2008 Mar;52(3):1182-3. doi: 10.1128/AAC.01332-07. Epub 2008 Jan 7.

Authors

W T M Jansen¹, A Verel, J Verhoef, D Milatovic

Affiliation

¹ University Medical Center Utrecht, Medical Microbiology Dept., G 04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. w.t.m.jansen@umcutrecht.nl

Abstract

We investigated the in vitro activity of AR-709, a novel diaminopyrimidine antibiotic currently in development for treatment of community-acquired upper and lower respiratory tract infections, against 151 Streptococcus pneumoniae strains from various European countries. AR-709 showed excellent activity against both drug-susceptible and multidrug-resistant pneumococci.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / chemistry
Anti-Bacterial Agents / pharmacology*
Community-Acquired Infections / microbiology
Drug Resistance, Multiple, Bacterial
Europe
Humans
Microbial Sensitivity Tests / methods
Pyrimidines / chemistry
Pyrimidines / pharmacology*
Respiratory Tract Infections / microbiology
Streptococcus pneumoniae / drug effects*

Substances

Anti-Bacterial Agents
Pyrimidines